GeneVentiv Therapeutics, Inc.
Wednesday, June 05, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. Our lead program, GENV-HEM, is the first AAV-based gene therapy to treat 33% of hemophilia patients (50K developed world) with neutralizing antibodies (inhibitors) to their missing clotting factor. GENV-HEM is also the first universal gene therapy for hemophilia, which has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.
Company Website:
http://www.geneventiv.com
Lead Product in Development:
GENV-HEM, is the first, single infusion, AAV-based gene therapy to treat 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor (50K developed world patients). GENV-HEM is also the first universal gene therapy for all hemophilias, has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.
Company HQ City
Raleigh
Company HQ State
NC
Company HQ Country
United States
CEO/Top Company Official
Damon R. Race
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
.jpg)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())